Lymphir

Active Ingredient(s): Denileukin Diftitox-cxdl
FDA Approved: * August 7, 2024
Pharm Company: * CITIUS PHARMS
Category: Cancer

Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these. In 1999, Ontak was approved by the U.S. Food and Drug Administration (F... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Related Brands

Drugs with the same active ingredients